'Targeted' molecular diversity: design and development of non-peptide antagonists for cholecystokinin and tachykinin receptors.

@article{Horwell1996TargetedMD,
  title={'Targeted' molecular diversity: design and development of non-peptide antagonists for cholecystokinin and tachykinin receptors.},
  author={D. Horwell and M. Pritchard and J. Raphy and G. Ratcliffe},
  journal={Immunopharmacology},
  year={1996},
  volume={33 1-3},
  pages={
          68-72
        }
}
A drug design strategy to non-peptide small molecule antagonists of neuropeptides is described that targets the molecular diversity which exists in the 'privileged' data set of the physico-chemical properties represented by the side-chains of the 20 genetically encoded amino acids. The strategy is exemplified by the design of a selective and high affinity cholecystokinin CCK-A antagonist PD 140548, CCK-B antagonist CI-988 (formerly PD 134308) tachykinin NK-1 antagonist PD 154075 and NK-2… Expand
12 Citations
Conotoxin therapeutics: a pipeline for success?
Artificial protein sensors.
Parallel solid-phase synthesis of diaryltriazoles
...
1
2
...

References

SHOWING 1-9 OF 9 REFERENCES
Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.
  • J. Hughes, P. Boden, +6 authors G. Woodruff
  • Chemistry, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1990
Minimum analogue peptide sets (MAPS) for quantitative structure-activity relationships.